Oncology Field In the field of Oncology, HSN focuses on the prevention and treatment of SREs in patients with tumor bone metastasis. HSN and Pharmanovia have established the strategic cooperation in 2018 to fully take charge of the commercialization and marketing promotion of the imported original drug Bondronat® (Sodium Ibandronate Injection, the latest generation, that is, the third generation of bisphosphonate) in China.
In the field of mental health, HSN has already made inroads into the rare disease domain. Since 2023, it has formed a strategic partnership with RareStone Group to jointly promote the commercialization of WAKIX® (Pitolisant Hydrochloride Tablets) with Citrine Medicine. In the future, HSN will focus on promoting the development of diagnosis and treatment for narcolepsy, providing effective medication for and benefiting more narcolepsy patients.
